Presbyopia - Pipeline Insight, 2022

Presbyopia - Pipeline Insight, 2022

DelveInsight’s, “Presbyopia - Pipeline Insight, 2022,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Presbyopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Presbyopia Understanding

Presbyopia: Overview

Presbyopia is a vision condition in which the shape of the crystalline lens of your eye changes. These changes make it difficult to focus on close objects. Presbyopia may seem to occur suddenly, but sight reduction occurs over several years. Presbyopia usually becomes noticeable in the early to mid-40s, but the reduction of your focus starts as early as childhood. Some signs of presbyopia include holding reading materials at arm's length, blurred vision at normal reading distance and eye fatigue along with headaches when doing close work. Presbyopia happens naturally in people as they age. The eye is not able to focus light directly on to the retina due to the hardening of the natural lens. Aging also affects muscle fibers around the lens making it harder for the eye to focus on up close objects. The ineffective lens causes light to focus behind the retina, causing poor vision for objects that are up close.

""Presbyopia - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Presbyopia pipeline landscape is provided which includes the disease overview and Presbyopia treatment guidelines. The assessment part of the report embraces, in depth Presbyopia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Presbyopia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Presbyopia.

In the coming years, the Presbyopia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics that are working to assess challenges and seek opportunities that could influence Presbyopia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

A detailed portfolio of major pharma players who are involved in fueling the Presbyopia treatment market. Several potential therapies for Presbyopia are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Presbyopia market size in the coming years.

Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Presbyopia) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Presbyopia Emerging Drugs Chapters

This segment of the Presbyopia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Presbyopia Emerging Drugs

CSF-1: Orasis Pharmaceuticals

CSF-1 is a novel presbyopia corrective eye drop being developed to improve the quality of life for people with presbyopia. CSF-1 is a preservative-free solution that contains a proprietary combination of low-dose pilocarpine and multi-faceted vehicle. Clinical trial results to date have demonstrated significant improvements in near vision and an excellent safety profile in people with presbyopia. In the Phase 3 studies, CSF-1 achieved statistically significant distance-corrected near visual acuity (DCNVA) and no loss of 1-line or more in distance or night vision.

UNR844-Cl: Novartis

UNR844-Cl is an ester of naturally occurring R-lipoic acid and choline. Previously called EV06 ophthalmic solution, UNR844 targets directly the flexibility and accommodative ability of the crystalline lens. It breaks disulfide bonds, which are thought to harden the lens over time. By disrupting these bonds, the lens becomes more elastic and regains some functionality.

Further product details are provided in the report……..

Presbyopia: Therapeutic Assessment

This segment of the report provides insights about the different Presbyopia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Presbyopia

There are approx. 12+ key companies which are developing the therapies for Presbyopia. The companies which have their Presbyopia drug candidates in the most advanced stage, i.e. phase III include, Orasis Pharmaceuticals.

Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Presbyopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Inhalation

Inhalation/Intravenous/Oral

Intranasal

Intravenous

Intravenous/ Subcutaneous

NA

Oral

Oral/intranasal/subcutaneous

Parenteral

Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

Antibody

Antisense oligonucleotides

Immunotherapy

Monoclonal antibody

Peptides

Protein

Recombinant protein

Small molecule

Stem Cell

Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Presbyopia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Presbyopia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Presbyopia drugs.

Presbyopia Report Insights

Presbyopia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Presbyopia Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Presbyopia drugs?

How many Presbyopia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Presbyopia?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Presbyopia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Presbyopia and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Orasis Pharmaceuticals

Novartis

Cellix Bio

Visus Therapeutics

AbbVie

Vyluma

Lenz Therapeutics

Ocuphire Pharma

JIXING Pharmaceuticals

Eyenovia

Key Products

CSF-1

UNR844-Cl

CLX-OPH-561

VTI-001

AGN-190584

NVK029

ACECLIDINE

Nyxol

MicroLine